Research Projects & Grants

Federal

• Supplement: Large scale single-cell gene rearrangement detection with a microfluidic device, Role: Candidate, National Institutes of Health/DHHS, (03/2022 - 02/2024) Status: Awarded

For Profit Organization

• J2J-MC-JZLH EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence, Role: Investigator, Eli Lilly & Co., (07/2023 - 07/2024) Status: Approved
• SDX-0103: A Phase 1/2 Study Assessing the Safety and Efficacy of Evexomostat (SDX-7320) in Combination with the PI3Ka Inhibitor Alpelisib (PIQRAY®) plus Fulvestrant in Postmenopausal Women at Risk for Hyperglycemia with Advanced Breast Cancer and a PIK3CA Mutation Who Have Progressed on or Following Endocrine Therapy plus a CDK4/6 Inhibitor, Role: Investigator, SynDevRx, Inc., (02/2024 - 02/2025) Status: Approved
• LUNGMAP, “A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Preciously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)” S1900F, “A Randomized Phase II Study of Carboplatin and Pemetrexed with or Without Selpercatinib (LY3527723) in Participants with Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study)”, Role: Investigator, Southwest Oncology Group, Status: Completed
• MNA-3521-014: An Open Label, Randomized Phase 2 Study to Evaluate the Safety and Efficacy of MTL-CEBPA Administered in Combination With Sorafenib or Sorafenib Alone in TKI naïve Participants With Previously Treated Advanced Hepatocellular Carcinoma (HCC) and Hepatitis B or Hepatitis C Virus (OUTREACH2), Role: Investigator, MINA ALPHA LIMITED, (06/2023 - 06/2024) Status: Approved
• Amgen Inc., 20190135: A Phase 1b Study Evaluating the Safety, Tolerability, and Efficacy of AMG 510 (plNN Sotorasib) in Combination with Panitumumab and in Combination with Panitumumab and FOLFIRI in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol H), Role: Investigator, Amgen, Inc., (06/2023 - 06/2024) Status: Approved
• Amgen 20190135: A Phase 1b, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation Amgen 20190135-C: A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101 Subprotocol C), Role: Investigator, Amgen, Inc., (02/2024 - 02/2025) Status: Approved
• Merck Sharp & Dohme Corp. MK-7339-013: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment- Naïve limited-Stage Small Cell Lung Cancer (LS-SCLC), Role: Investigator, Merck, Sharp & Dohme Corp., (02/2024 - 02/2025) Status: Approved
• Apollomics Inc. APL-101-01 (SPARTA): Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors, Role: Investigator, Apollomics Inc., (09/2023 - 09/2024) Status: Approved
• Amgen 20190135: A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (plNN Sotorasib) in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation, Role: Investigator, Amgen, Inc., (03/2024 - 03/2025) Status: Approved
• ATARA Biotherapeutics, Inc. ATA129-EBV-302: Multicenter, Open Label, Phase 3 study of Tabelecleucel for solid organ or allogeneic hematopoietic cell transplant subjects with Epstein-Barr virus-associated post-transplant lymphoproliferative disease after failure of Rituximab or Rituximab and Chemotherapy (ALLELE study), Role: PI, Atara Biotherapeutics, Inc., (01/2024 - 01/2025) Status: Approved
• SWOG A041701: A randomized phase II/III study of conventional chemotherapy +/- uproleselan (GMI-1271) in older adults with acute Myeloid Leukemia receiving intensive induction chemotherapy, Role: Investigator, Southwest Oncology Group, Status: Completed
• C3441021: A Phase 3, Randomized, Double-Blind, Placebo-Controlled study of Talazoparib with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (TALAPRO-2), Role: Investigator, Pfizer Inc., U.S. Pharmaceuticals Group, (07/2021 - 07/2022) Status: Completed
• SWOG/NRG LU003: A Biomarker-Driven protocol for previously treated ALK-Positive Non-Squamous NSCLC patients: The NCI-NRG ALK protocol, Role: Investigator, Southwest Oncology Group, Status: Completed
• Soligenix Inc. IDR-OM-02: A pivotal, double-blind, randomized, placebo-controlled multi-national study of SGX942 (Dusquetide) for treatment of oral mucositis in patients being treated with concomitant Chemoradiation for the treatment of squamous cell carcinoma of the head and neck, Role: PI, Soligenix, Inc., (07/2023 - 07/2024) Status: Approved
• Astellas 8951-CL-0301: A phase 3, global, multi-center, double-blind, randomized, efficacy study of Zolbetuximab plus mFOLFOX6 compared with placebo plus mFOLFOX6 as first-line treatment of subjects with Claudin (CLDN) 18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, Role: Investigator, Astellas Pharma US, Inc., (06/2022 - 06/2023) Status: Completed
• Janssen Research & Development, LLC 54767414LUC2001: A phase 1b/2, open-label, randomized study of daratumumab administered in combination with atezolizumab compared with atezolizumab alone in subjects with previously treated advanced or metastatic non-small cell lung cancer, Role: Investigator, Janssen Research & Development, LLC, (05/2018 - 05/2019) Status: Completed
• SWOG: A221101: A phase III randomized, double-blind placebo controlled study of armodafinil (Nuvigil®) to reduce cancer-related fatigue in patients with high grade glioma, Role: Investigator, Southwest Oncology Group, (05/2019 - 05/2020) Status: Completed
• SWOG -EAY131: Molecular analysis for therapy choice (MATCH), Role: Investigator, Southwest Oncology Group, (08/2019 - 08/2020) Status: Completed
• SWOG S1318: A phase II study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for patients >= 65 years of age with newly diagnosed Philadelphia-chromosome negative acute lymphoblastic leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for patients >= 65 years of age with newly diagnosed Philadelphia-chromosome positive (Ph+) ALL, Role: Investigator, Southwest Oncology Group, (08/2018 - 08/2019) Status: Completed
• Bio-Cancer Treatment International Ltd.-BCT-100-005: Recombinant human arginase 1 (rhArg1) in patients with advanced, arginine auxotrophic solid tumors: Dose escalation, safety and PK/PD, Role: Investigator, Bio-Cancer Treatment International, Ltd., (04/2020 - 04/2021) Status: Completed

Internal

• LLU Cancer Center biospecimen laboratory - specimens collection protocol, Role: Investigator, LLU Cancer Institute, (09/2023 - 09/2024) Status: Approved
• Registry for patients who have received endocrine therapy for H2 low Breast cancer to assess relationship between oncotype score and Breast cancer index, Role: PI, LLU Dept. of Medicine, (04/2024) Status: Approved
• Registry to analyze outcomes in hormone-receptor positive breast cancer patients who have received neoadjuvant therapy, Role: PI, LLU Dept. of Medicine, (04/2024) Status: Approved
• Evaluation of the influence of variable factors on emergency room visits and hospital admissions in sickle cell patients: a retrospective cohort study, Role: PI, LLU Dept. of Medicine, (12/2021) Status: Approved
• The Association Between Insurance coverage and Access to Cancer Treatment and Outcomes, Role: PI, LLU Dept. of Medicine, (04/2022) Status: Approved
• Investigator Initiated: The bone-targeting agents and the need for electrolyte monitoring in cancer patients: A retrospective cohort study of cancer patients treated between January 1,2014 to June 24, 2020, Role: Investigator, LLU Dept. of Pharmacy Practice, (07/2020) Status: Approved
• Convalescent Plasma to Treat Coronavirus - Associated Severe Pulmonary Complications: A Correlation Study of Serologic Anti-SARS-CoV-2 antibody to Treatment Efficacy and Outcome, Role: Investigator, LLU Basic Science, (06/2020) Status: Approved
• ELISA-based detection of COVID-19 antibodies, Role: Investigator, LLU Basic Science, (04/2020) Status: Approved
• Investigator Initiated: Retrospective analysis to determine the impact of age on safety and efficacy of immunotherapy given in non-hematologic malignancies, Role: PI, LLU Dept. of Medicine, (11/2019) Status: Approved
• Post-transplant Lymphoproliferative Disorder (PTLD) in patients who received organ transplant, Role: PI, LLU School of Medicine, (09/2020 - 09/2021) Status: Completed
• Investigator initiated: cetuximab vs cisplatin for squamous cell locally advanced head and neck cancer: A retrospective cohort study, Role: PI, LLU Dept. of Medicine, (08/2020 - 08/2021) Status: Completed
• Investigator initiated CIPNGRASP: A pilot study of intraneural facilitation for managing chemotherapy-induced peripheral neuropathy, Role: Investigator, LLU Dept. of Medicine, (04/2023 - 04/2024) Status: Completed
• A phase II trial of proton chemotherapy (PCT) for resectable esophageal or esophagogastric junction cancer, Role: Investigator, LLU Dept. of Radiation Medicine, (09/2023 - 09/2024) Status: Approved
• Combination of Anti-PD1 Therapy and Tumor Infiltrating Lymphocytes for the Treatment of Acute Myeloid Leukemia., Role: Other Significant Contributor, LLU - GRASP, (01/2020 - 12/2024) Status: Awarded
• Combination therapy of low dose 5-Azacytidine and cell therapy, Role: PD/PI, LLU Dept. of Medicine, (02/2018 - 02/2023) Status: Closed

Non-Profit Organization

• Improving quality of life for persons with SCD through Resilience and Empowerment (SCD-RE) Program, Role: Investigator, Networking California for Sickle Cell Care, (04/2022) Status: Approved
• Treatment for Sleep-Disordered Breathing in Adults with Sickle Cell Disease, Role: PD/PI, Bristol-Myers Squibb Foundation, Inc., (10/2021 - 10/2023) Status: Awarded
• Expanding Access to Sickle Cell Disease Care in California - Education and Awareness, Role: MD Recruiter, The Center for Comprehensive Care & Diagnosis of Inherited Blood Disorders, (07/2021 - 06/2023) Status: Closed
• Comprehensive Sickle Cell Clinic, Role: PD/PI, The Center for Comprehensive Care & Diagnosis of Inherited Blood Disorders, (07/2021 - 06/2024) Status: Awarded
• Gene transduced mesenchymal progenitor cell for Vitamin D delivery in acute myeloid leukemia, Role: PD/PI, American Society of Clinical Oncology, (07/2017 - 06/2018) Status: Closed

State

• Cell therapy for acute myeloid leukemia using hematopoietic stem cell as a vehicle, Role: Co-PD/PI, California Institute for Regenerative Medicine, (04/2018 - 03/2019) Status: Closed